前列腺SBRT推量后急性、亚急性与晚期泌尿系统生活质量的相关性
本研究为PROMETHEUS前瞻性II期试验的事后分析,纳入151例接受SBRT作为虚拟高剂量率近距离放疗推量的前列腺癌患者,中位随访60个月。采用EPIC-26评分和最小临床重要差异(MCID)分析发现,晚期尿失禁MCID与治疗结束时及12个月MCID、既往TURP和Rectafix相比SpaceOAR相关;晚期刺激症状MCID与基线刺激功能差和亚急性刺激相关;晚期梗阻症状MCID无关联。
要点
- 晚期尿失禁与治疗结束及12个月时尿失禁MCID、既往TURP、Rectafix相比SpaceOAR相关。
- 晚期刺激症状与基线刺激功能差及亚急性刺激症状相关。
- 晚期梗阻症状MCID未发现与急性或亚急性症状相关。
核心结论
- 前列腺SBRT推量后存在经历急性、亚急性和晚期泌尿系统毒性的患者亚群。
- 基线或亚急性刺激症状是长期刺激症状的预测因素。
- 既往TURP或基线刺激症状患者可能从密切评估和随访干预中获益。
研究设计与样本
- PROMETHEUS前瞻性II期试验(ACTRN12615000223538)的事后分析。
- 纳入151例接受SBRT作为虚拟高剂量率近距离放疗推量的前列腺癌患者,中位随访60个月。
- 使用EPIC-26评分和最小临床重要差异(MCID)评估急性(治疗结束时)、亚急性(12个月)和晚期(36和60个月)泌尿系统生活质量变化。
- 分别对尿失禁、梗阻和刺激域进行单变量和多变量逻辑回归分析。
主要发现
- 多变量分析显示,晚期尿失禁MCID与治疗结束时MCID相关(OR 3.55 [95% CI 1.42-8.92],p=0.01)和12个月MCID相关(OR 8.72 [95% CI 3.53-21.56],p<0.01)。
- 既往TURP(OR 6.11 [95% CI 1.56-23.89],p=0.01)和Rectafix相比SpaceOAR(OR 2.6 [95% CI 1.09-6.23],p=0.03)也与晚期尿失禁相关。
- 晚期刺激症状MCID与基线刺激功能差相关(OR 7.95 [95% CI 1.71-36.91],p<0.01)和亚急性刺激相关(OR 5.47 [95% CI 2.11-14.18],p<0.01)。
- 未发现与晚期梗阻症状MCID相关的因素。
关键数值与推荐
- 晚期尿失禁MCID与治疗结束时MCID:OR 3.55(95% CI 1.42-8.92),p=0.01。
- 晚期尿失禁MCID与12个月MCID:OR 8.72(95% CI 3.53-21.56),p<0.01。
- 晚期尿失禁MCID与既往TURP:OR 6.11(95% CI 1.56-23.89),p=0.01。
- 晚期尿失禁MCID与Rectafix相比SpaceOAR:OR 2.6(95% CI 1.09-6.23),p=0.03。
- 晚期刺激症状MCID与基线刺激功能差:OR 7.95(95% CI 1.71-36.91),p<0.01;与亚急性刺激:OR 5.47(95% CI 2.11-14.18),p<0.01。
临床怎么用
- 对既往TURP或基线刺激症状的前列腺SBRT患者,随访期间应密切评估和干预。
- 治疗结束时和12个月泌尿系统生活质量变化可能提示晚期尿失禁风险。
局限性
- 本文为事后分析,未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Emerging evidence demonstrates an association between acute and late genitourinary (GU) toxicity following prostate radiotherapy. However, this is not established following SBRT, and subacute toxicities may represent a transient and independent entity. We conducted a post-hoc analysis of the PROMETHEUS prospective phase II trial (ACTRN12615000223538) to investigate correlations among acute, subacute, and late GU QOL in patients who received SBRT as a virtual-high-dose-rate brachytherapy boost for prostate cancer. METHODS: The trial consisted of 151 men, with a median follow-up of 60 months. Relationships between acute (end of treatment [EOT]), subacute (12 months), and late (36 and 60 months) GU QOL changes were examined using EPIC-26 scores and minimal clinically important differences (MCID). Univariable and multivariable logistic regression were performed separately for incontinence, obstructive, and irritative domains. KEY FINDINGS: On multivariable analysis, late incontinence MCID was associated with MCID at EOT (OR 3.55 [95% CI 1.42-8.92], p = 0.01) and 12 M (8.72 [3.53-21.56], p < 0.01). Prior TURP (6.11 [1.56-23.89], p = 0.01) and Rectafix versus SpaceOAR (2.6 [1.09-6.23], p = 0.03) were also associated with late incontinence. Late irritative MCID was associated with poor baseline irritative function (7.95 [1.71-36.91], p < 0.01) and subacute irritation (5.47 [2.11-14.18], p < 0.01). No associations were identified with late obstructive MCID. CONCLUSIONS: This study identifies subsets of men who experience acute, subacute and late GU toxicity after prostate SBRT. Baseline or subacute irritative symptoms are predictors of longer-term irritation. Patients with prior TURP or baseline irritative symptoms may benefit from close assessment and intervention during follow-up.
引用
- Chan L, Martin J, Sidhom M, et al. Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost? Radiother Oncol. 2026. PMID: 42320679. doi:10.1016/j.radonc.2026.111650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。